At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Trial of MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With NSCLC
In Brief
A Phase 2 clinical trial evaluating 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, and 5 other interventions for Malignant Solid Neoplasm and 2 related conditions. Completed, enrolled 124 participants across 1 site.
Detailed Summary
This randomized phase I/II trial studies the side effects and best dose of pembrolizumab when given together with stereotactic body radiation therapy or non-stereotactic wide-field radiation therapy (conventional radiation therapy) and to see how well they work in treating patients with non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving pembrolizumab together with radiation therapy may kill more tumor cells.
Study Details
Timeline
Interventions
Undergo 3D-CRT
Undergo IMRT
Correlative studies
Given IV
Undergo PBRT
Undergo low dose radiation therapy
Undergo SBRT